VisiRose introduces therapy for infectious keratitis

VisiRose, a collaboration between Provectus Biopharmaceuticals and Bascom Palmer Eye Institute, is introducing a therapy for the treatment of infectious keratitis and other eye infections, according to a press release.

Rose bengal photodynamic antimicrobial therapy (RB PDAT), a noninvasive investigational treatment, uses a formulation of synthetic small molecule rose bengal sodium from Provectus and a light-based medical device from Bascom Palmer to treat eye infections, according to the release. VisiRose said the therapy may address antimicrobial resistance by providing a broad-spectrum ocular therapy for infections caused by bacteria, fungi or parasites.

“RB PDAT is a revolutionary, noninvasive treatment showing remarkable promise for patients with severe infectious keratitis,” Jean-Marie Parel, IngETS-G, PhD, FAIMBE, FARVO, director and co-founder of the Ophthalmic Biophysics Center at Bascom Palmer, said in the release. “This innovative therapy harnesses the power of light to combat infection and offers new hope for preserving vision.”

RB PDAT has shown promising results in more than 500 patients in eyes that did not respond to traditional therapies, according to the release. Clinical trials have taken place in the United States, India, Brazil and Mexico.

“RB PDAT offers a beacon of hope for patients facing the threat of vision loss from infectious keratitis,” Dominic Rodrigues, acting CEO of VisiRose, said in the release. “This innovative therapy, with its targeted action and dual benefits, represents a significant advancement in eye care, paving the way for a brighter future for those struggling with this challenging condition.”

Published by:

Read more about

This post was originally published on this site